Associated Papers
Identification of additional DPYD polymorphisms that increase the risk of severe fluoropyrimidine toxicity and improved predictive accuracy when combined with previously validated variants.
Nguyen-Hoang N et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2026
Do Socio-Economic Determinants Influence DPYD Testing? A Real-World Study of 1478 Cancer Patients Receiving Fluoropyrimidine Chemotherapy.
Baraka B et al.
Medical Sciences (basel, Switzerland), 2026
Optimizing fluoropyrimidine therapy: Real-world impact of DPYD genotype-based dosing on severe toxicity rates.
van Kan AHE et al.
British Journal of Clinical Pharmacology, 2026
Development of a comprehensive cardiovascular disease genetic risk assessment test.
Amendola LM et al.
Genetics in Medicine Open, 2026
A predictive model for life-threatening fluoropyrimidine toxicity based on DPYD sequencing in colorectal cancer.
Boige V et al.
Journal of the National Cancer Institute, 2025
Potential clinical relevance of rare dihydropyrimidine dehydrogenase genetic variants identified using whole-exome NextGen sequencing in cancer patients with severe fluoropyrimidine toxicity.
Cui E et al.
Cancer Chemotherapy and Pharmacology, 2025
Clinical implementation and outcome evaluation of dihydropyrimidine dehydrogenase (DPYD) pharmacogenomic testing for fluoropyrimidine dosing in a Canadian Provincial Healthcare center.
Wu F et al.
Clinical Biochemistry, 2025
Severe toxicity following genotype-guided reduced 5-FU dose in a heterozygous DPYD c.2846A>T carrier with stage III anal carcinoma: A case report.
Norris ML et al.
Cancer Chemotherapy and Pharmacology, 2025
Novel approaches for the discovery of pharmacogenetic biomarkers of chemotoxicity in patients with colorectal cancer.
Simoes AR et al.
British Journal of Pharmacology, 2025
Integration of germline pharmacogenomic burden to predict fluoropyrimidine-related toxicity - A secondary analysis of the PREPARE trial.
De Mattia E et al.
Oncogene, 2025
Risk vs Prevalence: Weighing Routine DPYD Variant Testing Prior to Fluoropyrimidine-Based Chemotherapy.
Larkey NE et al.
Clinical Chemistry, 2025
Opportunities and Challenges of Population Pharmacogenomics.
Zhou Y et al.
Annals of Human Genetics, 2025
A Lack of Complete Linkage Disequilibrium Between c.1236G>A and c.1129-5923C>G HapB3 Variants of DPYD: A Call to Revise European Pharmacogenetic Guidelines.
Gil-Rodriguez A et al.
International Journal of Molecular Sciences, 2025
Implementing Pre-Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects.
Bernsen EC et al.
Clinical Pharmacology and Therapeutics, 2025
Unrecognized mutations in DPYD* 2 A wild-type rectal cancer patients receiving postoperative 5-FU-based chemotherapy - do they have a clinical impact?
Liersch P et al.
Cancer Chemotherapy and Pharmacology, 2025
The Path to Clinical Implementation of <italic>DPYD</italic> Pharmacogenetic Testing: Long-Term Experience from an External Quality Assessment Provider and a University Testing Center.
Hedtke M et al.
Oncology Research and Treatment, 2025
Impact of Upfront DPYD Genotyping on Fluoropyrimidine Adjuvant Therapy in Colorectal Cancer: A Real-World Data.
Saarenheimo J et al.
Clinical Colorectal Cancer, 2025
Pharmacogenomic Testing in the Clinical Laboratory: Historical Progress and Future Opportunities.
Moyer AM et al.
Annals of Laboratory Medicine, 2025
Application of dihydropyrimidine dehydrogenase deficiency testing for the prevention of fluoropyrimidine toxicity: a real-world experience in a Southern Italy cancer center.
Bianchino G et al.
Journal of Chemotherapy (florence, Italy), 2025
Differences in DPYD Population Frequencies Observed in Galicians Compared to Europeans and Spanish from PhotoDPYD Study.
Gil-Rodriguez A et al.
Pharmaceuticals (basel, Switzerland), 2025
Genetic and Functional Characterization of DPYD Exon 4 Deletion Common in the Finnish Population.
Kiiski JI et al.
Basic & Clinical Pharmacology & Toxicology, 2025
Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice.
Leong IUS et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2025
Dihydropyrimidine enzyme activity and its effect on chemotherapy toxicity: importance of genetic testing.
Shamaei Zadeh A et al.
Cancer Chemotherapy and Pharmacology, 2025
DPYD genotype should be extended to rare variants: report on two cases of phenotype / genotype discrepancy.
Vilquin P et al.
Cancer Chemotherapy and Pharmacology, 2025
Comprehensive pharmacogenomics profiling of the Serbian population.
Jelovac M et al.
Frontiers in Pharmacology, 2025
Balance of care activity after EMA recommendation for DPYD gene testing in Galicia.
Gil-Rodríguez A et al.
Frontiers in Pharmacology, 2025
Clinical impact of pharmacogenomics in pediatric care: insights extracted from clinical exome sequencing.
Maggo S et al.
Frontiers in Genetics, 2025
Pharmacogenomic landscape of the Thai population from genome sequencing of 949 individuals.
Piriyapongsa J et al.
Scientific Reports, 2024
Exploring a novel model for newborn genetic screening in Ningxia, northern China: A retrospective observational study.
Mao X et al.
Medicine, 2024
The Frequency of DPYD c.557A>G in the Dominican Population and Its Association with African Ancestry.
Guevara M et al.
Pharmaceutics, 2024
Pharmacogenetic DPYD allele variant frequencies: A comprehensive analysis across an ancestrally diverse Iranian population.
Sarhangi N et al.
Daru : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2024
DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocol.
White C et al.
Bmc Cancer, 2024
Pharmacogenetic analysis of structural variation in the 1000 genomes project using whole genome sequences.
Sherman CA et al.
Scientific Reports, 2024
DPYD Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, American College of Medical Genetics and Genomics, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, Pharmacogenomics Knowledgebase, and Pharmacogene Variation Consortium.
Pratt VM et al.
The Journal of Molecular Diagnostics : Jmd, 2024
Characterization of Reference Materials for DPYD: A GeT-RM Collaborative Project.
Gaedigk A et al.
The Journal of Molecular Diagnostics : Jmd, 2024
Pharmacogenetics of DPYD and treatment-related mortality on fluoropyrimidine chemotherapy for cancer patients: a meta-analysis and trial sequential analysis.
de Moraes FCA et al.
Bmc Cancer, 2024
Dihydropyrimidine Dehydrogenase Polymorphism c.2194G>A Screening Is a Useful Tool for Decreasing Gastrointestinal and Hematological Adverse Drug Reaction Risk in Fluoropyrimidine-Treated Patients.
Ardizzone A et al.
Current Issues in Molecular Biology, 2024
MIR27A Gene Polymorphism Modifies the Effect of Common DPYD Gene Variants on Severe Toxicity in Patients with Gastrointestinal Tumors Treated with Fluoropyrimidine-Based Anticancer Therapy.
Ikonnikova A et al.
International Journal of Molecular Sciences, 2024
DPYD genetic polymorphisms in non-European patients with severe fluoropyrimidine-related toxicity: a systematic review.
Chan TH et al.
British Journal of Cancer, 2024